Arbex Sets an Ambitious Course: What Suzano and Kimberly-Clark's New Venture Means for the Global Tissue Industry

The global tissue and hygiene market has entered a new competitive phase with the official launch of Arbex, the joint venture combining Suzano's pulp operations and Kimberly-Clark's international tissue business. The deal's size drew headlines when it was announced; now that Arbex is operational, its strategic priorities are starting to reveal how the competitive landscape may shift over the next several years.

Arbex CEO Ehab Abou-Oaf has set a target of growing global tissue market share from an estimated 24–25% today to more than 35%. No timeline has been disclosed, but the ambition itself signals confidence — and puts pressure on the company to show it can execute at scale.

A Strategic Separation, Not Just a Transaction

Arbex is best understood as a deliberate carve-out rather than a simple merger of assets. By operating independently of its parent companies, the venture can direct capital, management focus, and investment decisions squarely at tissue and hygiene products, without competing for resources against broader corporate priorities.

Each parent brings something distinct. Suzano supplies one of the world's strongest pulp production platforms, giving Arbex reliable access to a critical raw material and room to optimize its supply chain. Kimberly-Clark contributes established consumer brands, product development expertise, and decades of operating experience across tissue markets worldwide.

Execution, Not Scale, Will Decide the Outcome

Growing market share is the headline goal, but the tissue industry has grown more competitive over the past decade, and size alone won't secure it. Mature markets are seeing only modest volume growth. Emerging markets offer more upside but come with currency swings, volatile input costs, and shifting consumer habits.

That means the real work lies in operational efficiency, faster innovation cycles, and the ability to respond to regional market conditions — not simply adding capacity.

Arbex's early strategy suggests it understands this. Its stated priorities — regional procurement, reduced plastic usage, waste minimization, and ongoing productivity gains — aren't just sustainability talking points. They directly affect manufacturing costs and long-term competitiveness.

Capital Investment as a Signal of Intent

Arbex has committed to annual capital investment of roughly US$100–120 million, aimed at production facilities, product development, and innovation.

That level of sustained spending matters in a market where converting equipment, digital manufacturing, automation, and packaging innovation increasingly determine profitability. Companies that delay modernization tend to fall behind on cost and flexibility relative to competitors who keep investing. The announced spending suggests Arbex intends to build out its manufacturing base while tailoring products to regional demand.

Managing Inflation Through Efficiency, Not Price

Arbex has signaled it will lean on operational efficiency — rather than price increases — to absorb inflationary pressure, including energy costs tied to geopolitical disruption.

This fits a broader industry pattern. Consumers remain price-sensitive, especially in private-label and value segments, and manufacturers that protect margins through productivity gains rather than repeated price hikes tend to hold share better during economic downturns. In that sense, operational discipline has become as much a strategic requirement as a manufacturing one.

A Crowded Field

Arbex is entering a market with established players like Procter & Gamble and Essity, along with strong regional competitors. Expect competition to sharpen across product innovation and premiumization, sustainable packaging, manufacturing efficiency, supply chain resilience, and brand differentiation.

Tissue is no longer a commodity category. Premium features, environmental performance, and localized product development now shape purchasing decisions for both retailers and consumers — raising the bar for any company chasing share gains.

Where the Growth Will Come From

Most of the industry's future demand growth is expected to come from developing economies, driven by rising incomes, urbanization, and growing hygiene awareness. For Arbex, these markets likely represent its biggest opportunity to expand.

But capturing that opportunity will require localized manufacturing and distribution — not standardized global products dropped into new markets.

Sustainability as a Commercial Advantage

Environmental performance is no longer a side consideration in pulp and paper investment decisions. Reducing plastic use, cutting manufacturing waste, and improving resource efficiency now influence both operating costs and customer relationships, as major retailers increasingly weigh sustainability metrics when choosing suppliers. Companies that combine sustainability with cost discipline are best positioned to hold their ground long-term.

The Bottom Line

Arbex's formation is one of the more significant structural shifts in the tissue industry in recent years, and its market-share target reflects real confidence in pairing Suzano's upstream strength with Kimberly-Clark's tissue expertise. But confidence isn't a strategy — disciplined execution across manufacturing, investment, innovation, and supply chains will determine whether that ambition becomes reality.

If Arbex delivers, its emergence could push the entire industry toward faster investment cycles and tighter operational efficiency. If it stumbles, the 35% target will serve as a reminder that in tissue, as in most manufacturing sectors, scale follows execution — not the other way around.